172 related articles for article (PubMed ID: 31089269)
1. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
[TBL] [Abstract][Full Text] [Related]
2. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
Catucci I; Casadei S; Ding YC; Volorio S; Ficarazzi F; Falanga A; Marchetti M; Tondini C; Franchi M; Adamson A; Mandell J; Walsh T; Olopade OI; Manoukian S; Radice P; Ricker C; Weitzel J; King MC; Peterlongo P; Neuhausen SL
Breast Cancer Res Treat; 2016 Nov; 160(1):121-129. PubMed ID: 27624329
[TBL] [Abstract][Full Text] [Related]
3. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.
Yang C; Arnold AG; Trottier M; Sonoda Y; Abu-Rustum NR; Zivanovic O; Robson ME; Stadler ZK; Walsh MF; Hyman DM; Offit K; Zhang L
Breast Cancer Res Treat; 2016 Dec; 160(3):447-456. PubMed ID: 27757719
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
6. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
7. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
[TBL] [Abstract][Full Text] [Related]
9. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
11. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
12. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.
Foulkes WD; Ghadirian P; Akbari MR; Hamel N; Giroux S; Sabbaghian N; Darnel A; Royer R; Poll A; Fafard E; Robidoux A; Martin G; Bismar TA; Tischkowitz M; Rousseau F; Narod SA
Breast Cancer Res; 2007; 9(6):R83. PubMed ID: 18053174
[TBL] [Abstract][Full Text] [Related]
16. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
Apostolou P; Pertesi M; Aleporou-Marinou V; Dimitrakakis C; Papadimitriou C; Razis E; Christodoulou C; Fountzilas G; Yannoukakos D; Konstantopoulou I; Fostira F
Clin Genet; 2017 Mar; 91(3):482-487. PubMed ID: 27357818
[TBL] [Abstract][Full Text] [Related]
17. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
[TBL] [Abstract][Full Text] [Related]
18. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
19. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
Behl S; Hamel N; de Ladurantaye M; Lepage S; Lapointe R; Mes-Masson AM; Foulkes WD
Sci Rep; 2020 Apr; 10(1):6491. PubMed ID: 32300229
[TBL] [Abstract][Full Text] [Related]
20. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene.
Fostira F; Kostantopoulou I; Apostolou P; Papamentzelopoulou MS; Papadimitriou C; Faliakou E; Christodoulou C; Boukovinas I; Razis E; Tryfonopoulos D; Barbounis V; Vagena A; Vlachos IS; Kalfakakou D; Fountzilas G; Yannoukakos D
J Med Genet; 2020 Jan; 57(1):53-61. PubMed ID: 31300551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
